Bertrand ME, Simoons ML, Fox KAA et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology.  Eur Heart J 2002;23:1809–1840.

Braunwald E, Antman EM, Beasley JW et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction:  A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patient With Unstable Angina).  2002.  Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf.  Accessed March 22, 2004.

Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498–1505.

Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non–Q-wave myocardial infarction. N Engl J Med 1998;338:1488–1497.

Blazing MA, de Lemos JA, White HD et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non–ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: A randomized controlled trial. JAMA 2004;292(1):55–64. Erratum in: JAMA 2004;292(10):1178.